The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) budesonide;formoterol fumarate dihydrate | Teva Pharma B.V. | Asthma; Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2020-04-03 | Order → |
| Rybelsus semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2020-04-03 | Order → |
| Trepulmix treprostinil Orphan | SciPharm Sàrl | Hypertension, Pulmonary | 🇪🇺 EU 2020-04-03 | Order → |
| Arsenic trioxide Mylan arsenic trioxide Generic | Mylan Ireland Limited | Leukemia, Promyelocytic, Acute | 🇪🇺 EU 2020-04-01 | Order → |
| Nilemdo bempedoic acid | Daiichi Sankyo Europe GmbH | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2020-04-01 | Order → |
| Ruxience rituximab BiosimilarAdditional monitoring | Pfizer Europe MA EEIG | Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis; Pemphigus | 🇪🇺 EU 2020-04-01 | Order → |
| Vaxchora cholera vaccine, oral, live | Bavarian Nordic A/S | Cholera | 🇪🇺 EU 2020-04-01 | Order → |
| Azacitidine Mylan azacitidine Generic | Mylan Pharmaceuticals Limited | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2020-03-27 | Order → |
| Nubeqa darolutamide | Bayer AG | Prostatic Neoplasms, Castration-Resistant | 🇪🇺 EU 2020-03-27 | Order → |
| Nustendi bempedoic acid;ezetimibe | Daiichi Sankyo Europe GmbH | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2020-03-27 | Order → |
| Staquis crisaborole Additional monitoring | Pfizer Europe MA EEIG | Dermatitis, Atopic | 🇪🇺 EU 2020-03-27 | Order → |
| Azacitidine betapharm azacitidine Generic | betapharm Arzneimittel GmbH | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2020-03-24 | Order → |
| Lyumjev (previously Liumjev) insulin lispro | Eli Lilly Nederland B.V. | Diabetes Mellitus | 🇪🇺 EU 2020-03-24 | Order → |
| Givlaari givosiran OrphanPRIMEAdditional monitoring | Alnylam Netherlands B.V. | Porphyrias, Hepatic | 🇪🇺 EU 2020-03-02 | Order → |
| Amsparity adalimumab Biosimilar | Pfizer Europe MA EEIG | Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthriti | 🇪🇺 EU 2020-02-13 | Order → |
| Azacitidine Accord azacitidine Generic | Accord Healthcare S.L.U. | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2020-02-13 | Order → |
| Beovu brolucizumab | Novartis Europharm Limited | Wet Macular Degeneration | 🇪🇺 EU 2020-02-13 | Order → |
| Recarbrio imipenem;cilastatin;relebactam | Merck Sharp & Dohme B.V. | Gram-Negative Bacterial Infections | 🇪🇺 EU 2020-02-13 | Order → |
| Polivy polatuzumab vedotin OrphanPRIME | Roche Registration GmbH | Lymphoma, B-Cell | 🇪🇺 EU 2020-01-16 | Order → |
| Sunosi solriamfetol Additional monitoring | Atnahs Pharma Netherlands B.V. | Narcolepsy; Sleep Apnea, Obstructive | 🇪🇺 EU 2020-01-16 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.